我们应如何评估不依赖组织学的癌症药物的临床和成本效益？ - Suppr | 超能文献

相似文献

1

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?我们应如何评估不依赖组织学的癌症药物的临床和成本效益？

BMJ. 2020 Jan 2;368:l6435. doi: 10.1136/bmj.l6435.

2

Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.1965年至2016年美国食品药品监督管理局批准时癌症药物的月度成本和中位数成本。

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.

3

New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.从全民医疗保健系统的角度看新癌症药物的审批：对全加肿瘤药物评审建议的分析。

J Natl Compr Canc Netw. 2018 Dec;16(12):1460-1466. doi: 10.6004/jnccn.2018.7084.

4

Oncology drugs enter the US market faster than in Europe but cost more.肿瘤药物进入美国市场的速度比欧洲更快，但成本更高。

JAMA. 2012 Aug 8;308(6):555. doi: 10.1001/jama.2012.9535.

5

Expensive cancer therapies: unintended effects.昂贵的癌症治疗方法：意外的影响。

J Natl Cancer Inst. 2015 Jan 6;107(1):497. doi: 10.1093/jnci/dju497. Print 2015 Jan.

6

Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.用于严重非致命疾病的创新型新药：研发成本与购买成本

JAMA Dermatol. 2016 Feb;152(2):139-40. doi: 10.1001/jamadermatol.2015.4903.

7

How cost-effective are new cancer drugs in the U.S.?新癌症药物在美国的性价比如何？

Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):39-55. doi: 10.1080/14737167.2020.1709965. Epub 2020 Jan 6.

8

Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.抗肿瘤药物的美国临床肿瘤学会（ASCO）和欧洲肿瘤内科学会（ESMO）价值框架探索。

J Oncol Pract. 2017 Jul;13(7):e653-e665. doi: 10.1200/JOP.2016.020339. Epub 2017 May 11.

9

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.致癌靶点、获益程度和抗肿瘤药物的市场定价。

J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23.

10

Differences in cancer drug assessment between Spain and the United Kingdom.西班牙和英国的癌症药物评估存在差异。

Eur J Cancer. 2015 Sep;51(13):1843-52. doi: 10.1016/j.ejca.2015.04.022. Epub 2015 Jun 25.

引用本文的文献

1

Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.不断发展的精准肿瘤药物评估途径，以改善患者的可及性：一种无肿瘤分类的视角。

Oncologist. 2024 Jun 3;29(6):465-472. doi: 10.1093/oncolo/oyae060.

2

HAMLET effect on cell death and mitochondrial respiration in colorectal cancer cell lines with KRAS/BRAF mutations.哈姆雷特对具有KRAS/BRAF突变的结肠癌细胞系中细胞死亡和线粒体呼吸的影响。

J Cancer Res Clin Oncol. 2023 Sep;149(11):8619-8630. doi: 10.1007/s00432-023-04777-0. Epub 2023 Apr 26.

3

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours.